STOCK TITAN

Schonfeld exits Mersana Therapeutics (MRSN) with reported 0% ownership

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Mersana Therapeutics, Inc. received an amended Schedule 13G from Schonfeld Strategic Advisors LLC reporting that it no longer beneficially owns any of the company’s common stock. Schonfeld reports ownership of 0 shares, representing 0% of the outstanding common stock, with no sole or shared voting or dispositive power.

Schonfeld describes itself as an investment adviser to several private funds and separately managed accounts, and notes that its clients were the record owners of the securities previously covered. The amendment confirms that Schonfeld’s beneficial ownership has fallen to 5% or less of Mersana’s common stock.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



Schonfeld Strategic Advisors LLC
Signature:/s/ Hung Luc
Name/Title:Hung Luc, Chief Compliance Officer
Date:02/17/2026
Mersana Therapeutics Inc

NASDAQ:MRSN

MRSN Rankings

MRSN Latest News

MRSN Latest SEC Filings

MRSN Stock Data

145.36M
4.92M
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE